Deals and Financings   Beijing 's BeiGene was approved to stage a $3 billion IPO on  Shanghai ’s STAR Exchange, the company's third listing following New York and Hong Kong IPOs; CBC announced its CBC China Life Science Infrastructure Venture fund held a first close of $500 million with a hard cap of $1.5 billion in total equity; Shanghai AoHua Endoscope completed a $117 million IPO on the Shanghai Star Exchange and rose 71% to a market cap of $800 million; Chengdu Clover Biopharma received $38.9 million from CEPI to complete development of its COVID-19 vaccine through market approval; Newsoara of Shanghai paid $5 million to expand partnership rights for Zenith Epigenetics' BET inhibitor to include Asia,  India  and ten Eurasian countries; Livzon Mabpharm of Zhuhai out-licensed its clinical stage PD-1 to Bright Peak Therapeutics of San Diego to develop PD-1 targeted immunocytokines;  Company News   EdiGene, a  China  gene editing company, will collaborate with University of Wisconsin researchers to identify candidates for genetic disease therapies;  Trials and Approvals   China  regulators may approve Beijing Brii Bio's COVID-19 dual antibody therapy under conditional use rules next month; Beijing HebaBiz Biotech was approved to start a China Phase III clinical study of Clevudine in patients with chronic hepatitis B virus; Taicang Connect Bio said its IL-4Rα candidate met its primary endpoint in a global Phase II trial for atopic dermatitis.  Stock Symbols: (NSDQ: BGNE; HK: 06160) (SHA: 688212) (HK: 2197) (HK: 2137) (NSDQ: CNTB) Share this with colleagues: // //